VALDISERRA, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 1.357
AS - Asia 1.140
EU - Europa 978
SA - Sud America 173
AF - Africa 87
OC - Oceania 15
Continente sconosciuto - Info sul continente non disponibili 4
Totale 3.754
Nazione #
US - Stati Uniti d'America 1.313
SG - Singapore 430
IT - Italia 301
CN - Cina 272
SE - Svezia 173
HK - Hong Kong 156
BR - Brasile 139
DE - Germania 109
IN - India 93
GB - Regno Unito 90
FI - Finlandia 79
FR - Francia 46
CI - Costa d'Avorio 37
NL - Olanda 37
JP - Giappone 34
BG - Bulgaria 33
VN - Vietnam 32
KR - Corea 25
TR - Turchia 24
CA - Canada 20
PL - Polonia 19
RU - Federazione Russa 19
AT - Austria 15
AU - Australia 15
MX - Messico 15
SN - Senegal 15
AR - Argentina 12
ID - Indonesia 12
NG - Nigeria 10
BD - Bangladesh 9
CZ - Repubblica Ceca 9
IR - Iran 9
LT - Lituania 9
PT - Portogallo 9
ZA - Sudafrica 9
IQ - Iraq 6
EC - Ecuador 5
MA - Marocco 5
SA - Arabia Saudita 5
VE - Venezuela 5
CL - Cile 4
IE - Irlanda 4
PK - Pakistan 4
UA - Ucraina 4
XK - ???statistics.table.value.countryCode.XK??? 4
AZ - Azerbaigian 3
CO - Colombia 3
DK - Danimarca 3
DZ - Algeria 3
ES - Italia 3
IL - Israele 3
JM - Giamaica 3
JO - Giordania 3
LV - Lettonia 3
MY - Malesia 3
UZ - Uzbekistan 3
AL - Albania 2
BE - Belgio 2
CH - Svizzera 2
ET - Etiopia 2
GH - Ghana 2
GR - Grecia 2
PH - Filippine 2
PY - Paraguay 2
TH - Thailandia 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
JE - Jersey 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LB - Libano 1
MK - Macedonia 1
OM - Oman 1
PE - Perù 1
SI - Slovenia 1
SO - Somalia 1
Totale 3.754
Città #
Ashburn 254
Singapore 244
Dallas 177
Hong Kong 154
Santa Clara 154
Shanghai 94
San Jose 66
Munich 62
Boardman 58
Los Angeles 57
Chandler 54
Florence 48
Beijing 44
Pisa 40
London 39
Turku 38
Abidjan 37
New York 37
Sofia 33
Helsinki 32
Serra 27
Kent 20
Massa 19
Princeton 19
Hyderabad 18
Fairfield 17
Frankfurt am Main 17
Istanbul 17
Mumbai 17
Hefei 16
Dakar 15
Lawrence 15
Tokyo 15
Milan 13
Warsaw 13
Buffalo 12
Denver 11
Medford 11
Rome 11
Lagos 10
Seoul 10
Wilmington 10
Chicago 9
Hanoi 9
Ogden 9
Redondo Beach 9
Atlanta 8
Fuzhou 8
Jakarta 8
San Francisco 8
Ho Chi Minh City 7
Livorno 7
Redwood City 7
Washington 7
Amsterdam 6
Bengaluru 6
Chennai 6
Council Bluffs 6
Houston 6
Jeju City 6
Johannesburg 6
Lappeenranta 6
Poplar 6
São Paulo 6
Vancouver 6
Belo Horizonte 5
Brooklyn 5
Buenos Aires 5
Cambridge 5
Düsseldorf 5
Lauterbourg 5
Marseille 5
Mexico City 5
Naples 5
New Malden 5
Nuremberg 5
Paris 5
Prague 5
Quanzhou 5
Rio de Janeiro 5
Roubaix 5
Torres Vedras 5
Vienna 5
Birmingham 4
Bremen 4
Cascina 4
Dublin 4
Ottawa 4
Phoenix 4
Pomona 4
Porto Azzurro 4
Pristina 4
Scarlino 4
Xiamen 4
Amman 3
Ann Arbor 3
Baku 3
Brasília 3
Brescia 3
Bresso 3
Totale 2.369
Nome #
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) 174
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study 162
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy 160
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases 141
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy 137
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs 136
Raynaud’s Phenomenon Associated with Calcitonin Gene-Related Peptide (CGRP) Antagonists: a Disproportionality Analysis on VigiBase 133
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline 132
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database 127
Assessing disease activity of rheumatoid arthritis patients and drug-utilization patterns of biologic disease-modifying antirheumatic drugs in the Tuscany region, Italy 123
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy 122
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study 120
Trajectories of Adherence to Biologic Disease-Modifying Anti-Rheumatic Drugs in Tuscan Administrative Databases: The Pathfinder Study 114
Disproportionality Analysis of ‘‘Early-Onset’’ Tardive Dyskinesia Stratified by Time to Onset Using FAERS Database. 112
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future 111
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases 108
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients 104
Exploring the relationship between utilization patterns of biologic disease-modifying anti-rheumatic drugs and disease activity in rheumatoid arthritis patients 103
Erratum to: Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System (Drug Safety, (2023), 46, 3, (283-295), 10.1007/s40264-022-01269-x) 102
Evaluation of the beneficial effects of a GABA-based product containing Melissa officinalis on post-inflammatory irritable bowel syndrome: a preclinical study 101
The pharmacological blockade of P2X4 receptor as a viable approach to manage visceral pain in a rat model of colitis 100
Discontinuation rate to biologic and targeted synthetic DMARDs in rheumatoid arthritis patients: Systematic review and meta-analysis 96
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance 95
Evaluation of drug-utilization and healthcare facilities use in patients with ulcerative colitis and treated with biologic therapy using data of an Italian healthcare administrative database: Results from michelangelo study 91
Analysis of the Drug Related Emergency Department Admissions in Tuscany: The FARO Project 90
Fatal Fat Overload Syndrome Following Intravenous Lipid Emulsion Administration as Antidote in Suspected Anesthetic Intoxication: A Fatal Medication Error. 90
Drug-Utilization, Healthcare Facilities Accesses and Costs of the First Generation of JAK Inhibitors in Rheumatoid Arthritis 84
Oral Presentation: Signal of Hypertension Associated with COVID-19 Vaccination: VigiBase (R) Data and Evidence from Real World 74
Assessment of Healthcare Facilities Associated with JAKi Drugs Used in Rheumatoid Arthritis Patients in Tuscany, Italy: The LEONARDO 73
Supporting the Spontaneous Reporting by Health Care Professionals of the University Hospital of Pisa, Italy: a Pilot Project from the Unit of Adverse Drug Reactions Monitoring 73
Communicating Drug Safety 68
Tixagevimab + cilgavimab against SARS-CoV-2: the preclinical and clinical development and real-world evidence 66
Lessons learnt from the preclinical discovery and development of ensitrelvir as a COVID-19 therapeutic option 62
COVID-19 Vaccines and Thromboembolic Events with Thrombocytopenia: Data from Italian Pharmacovigilance Public Database 59
Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall 58
Oral Presentation: Accesses to Emergency Department and Hospitalizations in New Users of Biologic Therapies for Ulcerative Colitis in Tuscany: The MICHELANGELO Study 58
Unresolved Gustatory, Olfactory and Auditory Adverse Drug Reactions to Antibiotic Drugs: A Signal Detection Analysis on Publicly Accessible Eudravigilance Data 44
Commentary: Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling 15
Totale 3.818
Categoria #
all - tutte 14.200
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.200


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202128 0 0 0 0 0 0 0 0 0 0 6 22
2021/2022328 4 2 54 60 55 24 15 12 15 9 22 56
2022/2023373 59 81 30 17 21 24 22 5 77 0 37 0
2023/2024407 3 11 23 3 30 46 58 36 32 26 67 72
2024/20251.574 34 64 85 132 99 159 159 58 160 171 186 267
2025/20261.108 163 137 216 189 208 105 90 0 0 0 0 0
Totale 3.818